Topotecan [(S)-9-dimethylaminomethyl-1O-hydroxycamptothecin hydrochloride; SK&F 104864-A, NSC 6096991, a water soluble semisynthetic analogue of the alkaloid camptothecin, is a potent topoisomerase I inhibitor. Here we show that topotecan stabilizes topoisomerase I/DNA cleavable complexes in radiation-resistant human B-lineage acute lymphoblastic leukemia (ALL) cells, causes rapid apoptotic cell death despite high-level expression of bcl-2 protein, and inhibits ALL cell in vitro clonogenic growth in a dose-depen-UMAN DNA topoisomerase I is a nuclear enzyme that plays a critical role in DNA replication by forming transient enzyme-bridged single-strand breaks of duplex DNA.'** These DNA breaks are believed to function as gates for the passage of the unbroken complementary DNA strands catalyzing relaxation of supercoiled DNA and, hence, the resolution of conformational and topologic problems that occur during DNA replication.'.' Topoisomerase I-targeting anticancer drugs such as camptothecin specifically interfere with the breakage-reunion (resealing) reaction of topoisomerase I, trapping the enzyme in a covalent reaction-intermediate, the cleavable ~omplex."~ Such stabilized cleavable complexes are believed to be responsible for the antitumor activity of topoisomerase I inhibit~rs.'~ This notion is predicated on the reported quantitative correlation between drugstabilized cleavable complex formation and antitumor activity of several camptothecin derivatives'" and the isolation of a camptothecin-resistant topisomerase I from a camptothecin-resistant tumor cell line.5
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Topotecan [(S)-9-dimethylaminomethyl-1O-hydroxycamptothecin hydrochloride; SK&F 104864-A, NSC 6096991, a water-soluble semisynthetic analogue of the alkaloid camptothecin, is a potent topoisomerase I p~i s o n .~*~* ' Topotecan causes cytotoxicity during the course of DNA replication by stabilizing the covalent complex between topoisomerase I and DNA and preventing the religation of enzyme-linked single-strand DNA break^.^^^,^ The purpose of this study was to examine the antileukemic activity of topotecan against human B-lineage acute lymphoblastic leukemia (ALL) cells. Our findings provide unprecedented evidence that topotecan causes rapid apoptosis of radiation-resistant ALL cells despite their high-level bcl-2 expression and inhibits their in vitro clonogenic growth in a dose-dependent fashion. Furthermore, we demonstrate that topotecan has potent antileukemic activity in three different severe combined immunodeficiency (SCID) mouse models of human poor-prognosis ALL, and at plasma concentrations readily achieved in patients, it markedly improves eventfree survival of SCID mice challenged with otherwise fatal doses of human leukemia cells. To our knowledge, this report is the first comprehensive preclinical analysis of the activity of a topoisomerase I inhibitor against human Blineage ALL cells. were used as target cell lines to evaluate the anti-ALL activity of topotecan. These cell lines were maintained by serial passages in RPM1 1640 medium (Gibco Laboratories, Grand Island, NY) supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum (Hyclone Laboratories, Logan, UT), 50 ,ug/mL streptomycin, 50 IUI mL penicillin, 2 mmol/L L-glutamine, and 10 mmol/L HEPES buffer. Cells were cultured in tissue culture flasks at 37°C in a humidified 5% CO, atmosphere. Before injection into SCID mice, cells were washed twice in phosphate-buffered saline (PBS) and resuspended in PBS. SCID mice were inoculated intravenously with 0.2 mL of this cell suspension containing 1 X IO6 NALM-6-UM1 cells, 5 X lo6 RS4; 11 cells, or 1 X lo6 LCI; 19 cells.
Patients. Four leukemia patients (three boys with ALL and one girl with AML) with a median age of 6 years (range, 4 to 20 years) received topotecan ( Proteins from whole cell lysates were separated on 10.5% polyacrylamide gels, transferred t o a 0.45-pm Immobilon-PVDF membrane, and imrnunoblotted with an antihuman bcl-2 antibody, as described in Materials and Methods.
and received no concomitant drugs that would alter topotecan disposition.
Drugs c m / rlrug rrenfrnenf protocols. Topotecan was obtained ( I ) from the Division of Cancer Treatment. NCI (Bethesda, MD) in vials containinp a lyophilized mixture of S mg of topotecan and I O 0 mg mannitol (for in vitro experiments) and ( 2 ) from Dr R. K. Johnson (SmithKline-Beecham, King of Prussia. PA) as pure topotecan powder (for in vivo SClD mouse experiments). For in vitro experiments. the topotecanlmannitol mixture was reconstituted with 2 mL sterile water. diluted in 100 mL of S% dextrose solution. The pH of the mixture was previously adjusted to 3 to 4 with hydrochloric acid and sodium hydroxide. For SCID mouse experiments, topotecan was carefully weighed and reconstituted with 0.9% normal saline at concentrations of 2 or 4 mglmL. This solution (100 pL) was then used to fill Alzet 3-day micro-osmotic pumps (Model IW3D. Alza Corp. Pa10 Alto. CA). The pumps were subcutaneously inserted into SClD mice anesthetized by intraperitoneal injection of 100 mgkg ketamine (Aveco Co. Fort Dodge. IA), and topotecan was administered as a continuous infusion over 72 hours. SCID mice. All SClD mice in this study were produced by specific pathogen-free (SPF) CB-17 s c i d inoculated intravenously with 0.2 mL leukemic cell suspensions con-daily. Event times were measured from the day of inoculation with taining I X IO" NALM-6-UMI. I X I O " LCI: IO. or S X I O " RS4: I I leukemia cells to the day of paraplegia or death. The probability of cells. These three SClD mouse models of human ALL have been event-free survival was determined. and event-free interval curves described in detail in previous reports.x.'" Survival of mice was were generated using the Kaplan-Meier product limit method. as monitored by observation twice per day. and the onset of paraplegia previously reported." 'l' We used the Mantel-Cox log-rank test to :IS a result of meningeal leukemia 21s well as death was recorded assess the effect of drug treatment on the probability of event-free
For personal use only. on October 30, 2017. by guest www.bloodjournal.org From survival of SCID mice inoculated with leukemia cells, as previously reported.""" At the time of death, necropsies were performed, and multiple organs of SCID mice were collected for evaluation of their burden of human leukemic cells by histopathologic studies and multiparameter flow cytometric analyses using two-color immunofluorescence staining techniques, as previously described."'"' Human DNA was detected by amplifying a I IO-bp fragment from the first exon of the human p-globin gene using two 20-base oligonucleotide primers that flank the region to be amplified, as previously described.x"" Controls included the polymerase chain reaction (PCR) reaction buffer without the genomic DNA as a background control; DNA from bone marrow, liver, spleen, and brain of healthy SCID mice as negative controls; and the PCR reaction mixture with NALM-6-UMI pre-B ALL cell line genomic DNA as a positive control.
Apoptosi.r os.sn.v.s. Topotecan-treated leukemic cells were examined on Wright-Giemsa-stained cytospin slides for morphologic changes characteristic of apoptosis. including nuclear chromatin condensation, segmentation of the nucleus, and plasma membrane blebs. The ultrastructural changes of apoptosis were documented by electron microscopy. as previously described."." In brief, cell suspensions were mixed I:I with 3% glutaraldehyde in White's saline [a 10% solution of a I : I mixture of ( I ) 2.4 mmol/L KCI, 46 mmollL MgSO,, 64 mmollL Ca(NO&, and (2) 0.13 molL NaHC03, 8.4 m m o l L NaH,PO,, and 0.1 g/L of phenol red, pH 7.4]."." After IS-minute fixation, the cells were centrifuged, supernatants were removed, and cells were resuspended with 3 4 frcshly prepared glutaraldehyde in White's saline. Samples resuspended in the aldehyde fixative were maintained at 4°C for 30 minutes. sedimented to pellets, washed in PBS, and then combined with 2% osmic acid with 1.5% potassium ferrocyanide for 2 hours at 4°C. All samples were dehydrated in a graded series of alcohol and embedded in Epon 812. Thin sections cut from the plastic blocks on an ultramicrotome were examined unstained or after staining with uranyl acetate and lead citrate to enhance contrast. Examination was performed in a Philips (Mahwah, NJ) 301 electron microscope, as described."." In addition, cells were harvested 4 hours after exposure to topotecan, and DNA was prepared for analysis of fragmentation, as described." DNA was then electrophoresed through a I % agarose gel, and the DNA bands were visualized by UV light a ter staining with ethidium bromide (0.5 pgImL). Hue Ill-digested OX 174 replicative form DNA mixed I : ] with Hiudlll-digested I DNA was used for sizing the DNA fragments on the ethidium bromide-stained agarose gels. as previously reported."
Western blot ar~a!\..ris of /?c/-2. The expression of bcl-2 protein in human leukemia cells was studied by immunoblotting with a monoclonal mouse 1 g G l~ anti-bcl-2 antibody (antihuman bcl-2 oncoprotein: DAKO-bcl-2, 124, Lot 063; DAKO AIS, Carpenteria, CA), as described previously." This antibody was generated against a synthetic peptide sequence comprising amino acids 41 to 54 of bcl-2 protein and was used at a concentration of 0.5 pgl mL. according to the manufacturer's instructions. In brief, whole cell lysates were prepared by pelleting I .0 mL of cell suspension for 8 seconds in a microcentrifuge, aspirating the supernatant, and adding IS0 pL of sodium dodecyl sulfate (SDS) lysis buffer (50 mmolIL Tris-HCI. 2% SDS. 10% glycerol) containing 25 mmoll L dithiothreitol, as previously reported." Each sample was boiled for 5 minutes. The DNA was sheared by several passages through a 28-gauge needle, and equivalent amounts of protein in 40 pL SDS reducing sample buffer (50 mmolIL Tris HCI, pH 6.8, 2% SDS. 10% glycerol, and 25 mmollL dithiothreitol) were loaded onto 10.5% polyacrylamide gels and electrophoresed overnight at 4 mA. The proteins were transferred to a 0.45-pm Immobilonpolyvinylidene difluoride (PVDF) membrane (Millipore Corp. Bedford, MA) for 75 minutes at 130 mA using a semidry transfer apparatus (Hoefer Scientific Instruments, San Francisco, CA). and immunohlotting was performed on the PVDF blots with a 1500 dilution (0.5 pgImL) of antihuman bcl-2 antibody (260 pgImL), CO" I 0 10 50 100'
Nanomolar concentrations of topotecan induce apoptotic cell death of radiation-resistant RS4;ll leukemia cells expressing high levels of bcl-2 protein. RS4; 11 cells were harvested 1 to 5 days after exposure to topotecan, and DNA was prepared for analysis of fragmentation. DNA was then electrophoresed through a 1% agarose gel, and the DNA bands were visualized by UV light after staining with ethidium bromide. CON, control. mglm'ld). Pumps were subcutaneously implanted into SCID mice 24 hours after inoculation with I X IO" NALM-6-UM I pre-B ALL cells. Blood samples (150 pL) were collected from mice (four animals per time point) hy retroorhital hlceds into heparinized tuhes. Sample times included pretopotecan. 29 hours after the start of the infusion. immediately after removal of the infusion pump i t 72 hours. and at I , I .S. 2.4. X. and 24 hours after pump removal. Plasma was collected hy immediately centrifuging the blood at 5.000,y for 2 minutes, and samples were pooled in 200-pL aliquots. To quantitate the topotecan lactone concentration in these samples. plnsma proteins were precipitated hy the addition of 200 p L of plasma to X00 p L of cold methanol (-30°C). This mixture was vonexed for 1 0 seconds and centrifuged for 2 minutes at I2.000,y in a rapid acceleration/deceler31ion centrifuge. and the supernatant was decanted into a plastic screw-top tuhe. A separate S00 pL of the plasma methanol extract was acidified with 20 p L of 20% phosphoric acid for analysis of total topotecan (lactone and hydroxy-acid). Plasma concentrations of topotecan were measured by a reverse-phase isocratic high performance liquid chromatography (HPLC) method using fluorescence detection." Calihration c u n w were constructed using spiked murine plasma over a range of 0.25 to I O ng/mL. The lower limit of sensitivity for the assay was 0.25 ng/mL. B-lineage ALL cells. As shown in Fig I, RS4 ; I 1 cells express higher levels of bcl-2 protein than fresh leukemic cells from two children with newly diagnosed B-lineage ALL (TS and ER) and have been previously shown to be radiationresistant."' NALM-6 pre-B ALL cells known to be not as radiation-resistant as RS4; 1 1 cells expressed less bcl-2 ( Fig  1) . On agarose gels, DNA from untreated control RS4; 1 1 or NALM-6 cells showed no fragmentation, whereas DNA from NALM-6 cells treated with greater than 1 pmol/L topotecan for 4 hours had a ladder-like fragmentation pattern consistent with an endonucleolytic cleavage of DNA into oligonucleosome-length fragments at multiples of 200 bp (Fig 2A) . Unlike NALM-6 cells, RS4; I 1 cells showed no ladder-like DNA fragmentation after topotecan treatment for 4 hours (Fig 2B) tion is a late event in apoptotic DNA from topotecan-treated RS4; 1 I cells showed a smear of DNA at the top of the gel suggestive of high molecular weight DNA degradation, which may be the earliest event in the apoptotic process (Fig 2B) . In some cases of apparent apoptosis, the chromatin may not be degraded into nucleosome-sized fragments, suggesting that this is not an essential component of the apoptotic process.""?' Therefore, the data presented in the agarose pel shown in Fig 2B may underestimate the degree of apoptosis induced by topotecan. To more accurately assess the ability of topotecan to induce apoptosis in RS4; 1 1 cells. we used transmission electron microscopy. As shown in Figs 3 and 4 , the examination of topotecan-treated RS4; 1 I cells by transmission electron microscopy confirmed the presence of multiple apoptosis-associated ultrastructural changes involving both the cytosol and the nucleus. The changes in the cytosol included development of translucent cytoplasmic vacuoles, condensation leading to compaction of organelles, disappearance of microvilli with concomitant formation of blunt protuberances from the cell surface (blebbing), and separation of surface protuberances with plasmalemmal sealing to produce membrane-bound apoptotic bodies of spherical or ovoidal shape. Besides condensed cytoplasm, a variety of organelles was included in the apoptotic bodies, including mitochondria and nuclear fragments. Examination of the nuclei from topotecan-treated cells showed chromatin condensation, round masses of fine granular material near the center of the nucleus (Fig 3C) , fragmentation of the nucleus (Fig 3B) , crescents of electron-dense heterochromatin that result from uniform condensation of chromatin around the inner margin of the nuclear envelope ( Fig  3C) . nuclear collapse (Fig 3D) . and formation of membraneenclosed apoptotic bodies, some of which contain nuclear fragments (Fig 4) . Despite these apoptotic changes in the cytosol and nucleus, the surface membrane and mitochondria remained intact (Figs 3 and 4) . Thus, topotecan can cause apoptosis in B-lineage ALL cells, including radiation-resistant t(4; 11) ALL cells with high-level expression of bcl-2 protein, which has been shown to inhibit most types of apoptotic cell death."
RESULTS

Raclirrtiott
Although the experiments shown in Figs 2 and 3 demonstrated that micromolar concentrations of topotecan can cause apoptotic cell death in ALL cells, such concentrations cannot be achieved in patients, and it is believed that topoisomerase I inhibitors will be most effective if used at low doses for extended periods of time rather than at high doses given over a short time. Therefore, it was important to examine the ability of topotecan to induce apoptosis when used at lower concentrations and longer exposure times. As shown in Fig 5, longer treatments with topotecan were more effective, and even S0 nmol/L topotecan caused apoptosis of RS4; 11 cells after 2 days. Trypan blue exclusion assays further confirmed that no loss in membrane integrity occurred until 2 days after continuous exposure to topotecan (Fig 5) , which is consistent with the published features of the apoptotic death process.2n'2h
Apoptosis of ALL cells after a 24-hour exposure to nanomolar concentrations of topotecan was also evident from distinctive morphologic changes visualized by light microscopy, including shrinkage of the cell, nuclear chromatin condensation, segmentation of the nucleus, and plasma membrane blebs in greater than 90% of cells (Fig 6) . Topotecaninduced apoptosis was not triggered by a decrease of iheir antiapoptotic bcl-2 oncoprotein levels after drug exposure (Fig 7) .
In vitro antileukemic activity of topotecan against clonogenic ALL cells. To further assess the activity of topotecan against radiation-resistant B-lineage ALL cells, we next performed clonogenic assays. As shown in Fig 8, topotecan killed clonogenic RS4; 1 I and NALM-6 cells in a dose-and time-dependent fashion. Notably, topotecan was more effective against RS4; 1 I cells than against NALM-6 cells, although RS4; l l cells express much higher levels of bcl-2 protein.
In vivo pharmacokinetic features and anti-ALL activih of topotecan. We previously reported that RS4; 1 1 [t(4; 11) ALL], NALM-6-UM 1 [pre-B ALL], and LC1 ; 19 [t( I ; 19) ALL] B-lineage ALL cells cause disseminated and fatal leukemia in SCID mice."'" These three SCID mouse models of human B-lineage ALL were used to evaluate the antileukemic efficacy of topotecan administered subcutaneously over 72 hours. The Kaplan-Meier estimate (?SE) of the probability of event-free survival after inoculation with 5 X IO6 RS4; 1 l cells was 52% t 10% at 2 months, and all 23 of the PBS-treated control SCID mice died within 108 days, with a median event-free survival of 64.5 days (Fig 9A) . Histopathologically, the involvement of bone marrows, spleens, and ovaries of SCID mice was manifested as replacement of normal tissue elements by diffuse sheets of densely packed leukemic cells. Leukemic infilrates were detected in multiple organs, as previously reported.'"' Multiparameter flow cytometric analyses of bone marrow, liver, spleen, and meninges confirmed the presence of human ALL cells (ie, CDlO+CD19' NALM-6 cells, CD19+CD45+ RS4; 11 cells, or LC1; 19 cells), and PCR analysis of bone marrow, liver, spleen, and brain confirmed the presence of human DNA (data not shown). Importantly, treatment with topotecan significantly improved event-free survival of SCID mice challenged with RS4;ll cells. Significantly higher cumulative proportions of topotecan-treated SCID mice remained alive without evidence of leukemia as compared with PBS-treated SCID mice (P < .000001 for 200 pg topotecan as well as 400 pg topotecan). Furthermore, time to event (paraplegia or death) in topotecan-treated groups was significantly delayed as compared with the PBStreated group (Fig 9A) . The Kaplan-Meier estimates (?SE) of the probability of event-free survival at 17.5 days after inoculation of RS4; 11 cells were 40% 5 22% for SCID mice treated with a total of 200 pg topotecan and 50% t 25% for SCID mice treated with a total of 400 pg topotecan (Fig 9A) . Similarly, a dose-dependent improvement in the event-free survival of SCID mice challenged with 5 X 10" LCI; 19 leukemia cells was observed (Fig 9B) . In accord with the in vitro clonogenic assay data, topotecan was most effective against RS4; 11 cells with the highest level of bcl-2 protein expression. Figure 9C shows the collective data from all three SCID mouse models. The Kaplan-Meier estimates (?SE) of the probability of event-free survival at 175 days after inoculation with leukemia cells (RS4; 11, NALM-6, and LC]; 19 cells) were 11% t 6% for SCID mice treated with a total of 200 pg topotecan (median survival, 45 days) and 57% t 17% for SCID mice treated with a total of 400 pg topotecan (median survival, greater than 175 days). By comparison, all of the 135 PBS-treated control mice died at a median of 40 days ( P < .0001). As 1,000 leukemia cells caused disseminated and fatal leukemia in these three SCID mouse models within 175 days,*"" the long-term event-free survival of topotecan-treated SCID mice challenged with I X lo6 to 5 X lo6 cells is consistent with 2 3 log kill of leukemia cells in vivo by topotecan therapy.
We next examined the pharmacokinetic features of topotecan in SCID mice. A one-compartment model fit the plasma concentration versus time data for topotecan. The apparent subcutaneous clearance for topotecan was 227.8 L/h/mz, steady-state plasma concentration was 2.6 p a , apparent volume of the central compartment was 493.2 Urn2, (AUCWT8) was 137 pg X h/L, and t was 1 .S hours. The median ratio of topotecan lactone to total topotecan (lactone + hydroxy acid) for all samples was 0.38 (range, 0.29 to 0.62). Figure 10 shows the topotecan concentration versus time plot for the SCID mice. For comparison with mouse data, a concentration versus time plot for four children with leukemia receiving topotecan is also presented. The results show that the plasma concentrations of topotecan producing responses in SCID mice are readily achievable in pediatric patients. The subcutaneous dosage administered to the SCID mouse (15.8 mg/m2/ d) was greater than the intravenous dosage administered to patients (l .75 mg/m2/d), which may reflect incomplete subcutaneous bioavailability in the SCID mice.
DISCUSSION
ALL is the most common childhood rnalignancy.*'~") In B-lineage ALL, the most prevalent form of ALL, dramatic
For personal use only. on October 30, 2017. by guest www.bloodjournal.org From improvements in multiagent chemotherapy have resulted in cure rates of 70% to 75%.28-3' Currently, the major challenges in the treatment of B-lineage ALL are to design more effective front-line therapy €or high-risk patients and to cure patients who have relapsed despite intensive multiagent chemoFor B-lineage ALL patients who have relapsed while on therapy or shortly after elective cessation of therapy, the overall survival is very poor."-34 The preferred treatment for these children has generally been intensive chemotherapy to achieve a second remission and subsequent use of ablative radiochemotherapy followed by bone marrow transplantation (BMT).3 '-34 Although improvements in long-term disease-free survival have been reported, recurrence of leukemia persists as the major dilemma that diminishes the success of BMT for the treatment of high-risk or relapsed B-lineage ALL, with only 10% to 15% of patients becoming long-term disease-free survivor^.'^ Recent preclinical studies demonstrated that (1) in 43% of newly diagnosed ALL cases, clonogenic leukemia cells display a marked radiation resistance,35 and (2) in 70% of newly diagnosed cases, clonogenic leukemia cells are able to repair sublethal radiation damage.36 Furthermore, certain subsets have been identified among B-lineage ALL patients-such as the immunophenotypically distinct CD34TD24-subset, which includes the vast majority of the t(4; 1 1) ALL patients-where ionizing radiation does not trigger apoptotic death of leukemic Notably, in vitro radiation resistance at the level of clonogenic leukemia cells (also referred to as leukemic progenitor cells) is associated with a high likelihood of relapse after total body irradiation and BMT.".38 Collectively, these preclinical and clinical observations in B-lineage ALL emphasize the need for therapeutic innovation to eradicate radiation-resistant leukemic clones from high-risk ALL patients undergoing BMT.
The enzyme topoisomerase I induces transient singlestrand DNA breaks that lead to relaxation of supercoiled DNA, an essential step for DNA replication and RNA transcription.',' Topotecan causes cytotoxicity during the course of DNA replication by stabilizing the covalent complex between topoisomerase I and DNA, thereby preventing the religation of enzyme-linked single-strand DNA breaks.' Topotecan has broad spectrum antitumor activity against murine tumors.' Furthermore, it has demonstrated potent antitumor activity in immunocompromised mouse xenograft models of human rhabdomyosarcoma, osteosarcoma, and colon adenocarcinoma^.^^^^ Moreover, some of the solid tumor patients enrolled in ongoing phase L A 1 clinical trials showed objective clinical response^.^^^^' However, the clinical potential of this promising new agent for the treatment of ALL has not been fully explored. In the present study, we evaluated the antileukemic activity of topotecan against human B-lineage ALL cells. Topotecan caused rapid apoptosis of B-lineage ALL cells, inhibited their in vitro clonogenic growth, and exhibited potent antileukemic activity in three different SCID mouse models of human B-lineage ALL. Moreover, the plasma concentration versus time plot producing a response in SCID mice is readily achieved in patients.
We have previously shown that topotecan systemic clearance in mice after intraperitoneal administration was 20.0 L/h/m', suggesting that the subcutaneous bioavailability was approximately 10% in the present study, accounting for the relatively high dose of topotecan in SCID mice.39 Despite relatively low bioavailability, cytotoxic plasma concentrations were obtained, as evidenced by the antileukemic responses noted in SCID mice, and these conditions can be achieved in patients. Apoptosis, also known as programmed cell death, is a common mode of eukaryotic cell death, with distinct ultrastructural features and a ladder-like DNA fragmentation pattern due to endonuclease-mediated cleavage of DNA into oligonucleosome-length fragments.'3~.20-26 Ionizing radiation'' and several chemotherapeutic drugs with diverse molecular targets have been reported to induce apoptotic cell death in human cells. The topoisomerase I inhibitor camptothecin was reported to cause apoptosis in acute myelocytic leukemia cells." Detailed studies by Kaufman" demonstrated that camptothecin-triggered apoptosis is not dependent on active protein or RNA synthesis and is likely mediated by the action of an extranuclear endonuclease that gains access to the nucleus. Here, we provide evidence that topotecan, a semisynthetic analogue of camptothecin, can induce apoptosis in human B-lineage ALL cells. Remarkably, topotecan was able to induce apoptosis even in highly radiation-resistant leukemia cells expressing high levels of bcl-2 protein, which has been shown to inhibit most types of apoptotic cell death.27 Importantly, there was no apparent correlation between bcl-2 protein expression and topotecan resistance. Indeed, RS4; 11 cells with the highest bcl-2 levels were found to be the most topotecan-sensitive ALL cells in this study. Topotecan-induced apoptosis was not triggered by decrease of bcl-2 in target ALL cells. The observed dose-and timedependent cytotoxicity by topotecan against ALL cells is likely due to the mechanism of action of topoisomerase 1 inhibitors (ie, requirement of replication fork arrest and inhi-
